ERT
Sector/industry
eClinical solutions for the pharmaceutical industry
ERT is a leading provider of high-quality patient
safety and efficacy endpoint data collection solutions for use in
clinical drug development. ERT delivers a
unique combination of technology, services and clinical consulting,
built on a foundation of deep scientific and regulatory expertise.
ERT's solutions increase the accuracy and reliability of patient
data and improve widely deployed solutions in healthcare areas such
as Cardiac Safety, Respiratory Solutions and electronic Clinical
Outcome Assessments (eCOA). ERT has a proven track record of
growth.
ERT's systems are widely used by pharmaceutical and
biotech companies innovating drug and device therapies to optimize
clinical trial management, and to document safety and efficacy
clinical outcomes data.
Since its inception in 1972, ERT has developed from a
technology start-up to a company that today supports the conduct of
more than 1,500 clinical trials annually. This is achieved through
the compilation of a variety of clinical outcome data from more
than 2.7 million patients, in strict accordance with the standards
defined by the major regulatory agencies.
Nordic Capital's ambition is to support ERT's
continued development, strategic goals, future growth and further
international expansion. Supported by Nordic Capital,
ERT will be well positioned to continue its development as a global
market leader within innovative and differentiated patient data
collection solutions.
Management:
- James Corrigan, CEO
- Waqar Nasim, CFO
Key Information:
Revenues
2016*:
EUR 330 million
Employees:
1930
Ownership:
Nordic Capital Fund VIII, controlling shareholding
Date of investment:
2016
Head office:
Philadelphia, Pennsylvania, USA